232 related articles for article (PubMed ID: 25157002)
1. Hydroxyurea and growth in young children with sickle cell disease.
Rana S; Houston PE; Wang WC; Iyer RV; Goldsmith J; Casella JF; Reed CK; Rogers ZR; Waclawiw MA; Thompson B;
Pediatrics; 2014 Sep; 134(3):465-72. PubMed ID: 25157002
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
3. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.
Lebensburger JD; Miller ST; Howard TH; Casella JF; Brown RC; Lu M; Iyer RV; Sarnaik S; Rogers ZR; Wang WC;
Pediatr Blood Cancer; 2012 Oct; 59(4):675-8. PubMed ID: 22190441
[TBL] [Abstract][Full Text] [Related]
4. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.
Alvarez O; Miller ST; Wang WC; Luo Z; McCarville MB; Schwartz GJ; Thompson B; Howard T; Iyer RV; Rana SR; Rogers ZR; Sarnaik SA; Thornburg CD; Ware RE;
Pediatr Blood Cancer; 2012 Oct; 59(4):668-74. PubMed ID: 22294512
[TBL] [Abstract][Full Text] [Related]
5. Immunologic effects of hydroxyurea in sickle cell anemia.
Lederman HM; Connolly MA; Kalpatthi R; Ware RE; Wang WC; Luchtman-Jones L; Waclawiw M; Goldsmith JC; Swift A; Casella JF;
Pediatrics; 2014 Oct; 134(4):686-95. PubMed ID: 25180279
[TBL] [Abstract][Full Text] [Related]
6. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.
Wang WC; Helms RW; Lynn HS; Redding-Lallinger R; Gee BE; Ohene-Frempong K; Smith-Whitley K; Waclawiw MA; Vichinsky EP; Styles LA; Ware RE; Kinney TR
J Pediatr; 2002 Feb; 140(2):225-9. PubMed ID: 11865275
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.
Wang WC; Oyeku SO; Luo Z; Boulet SL; Miller ST; Casella JF; Fish B; Thompson BW; Grosse SD;
Pediatrics; 2013 Oct; 132(4):677-83. PubMed ID: 23999955
[TBL] [Abstract][Full Text] [Related]
8. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
McGann PT; Flanagan JM; Howard TA; Dertinger SD; He J; Kulharya AS; Thompson BW; Ware RE;
Pediatr Blood Cancer; 2012 Aug; 59(2):254-7. PubMed ID: 22012708
[TBL] [Abstract][Full Text] [Related]
9. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
10. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
11. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
12. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
13. Effect of Hydroxyurea Therapy on Growth Parameters in Older Children (6-15 Year-Old) with Sickle Cell Disease: Low Dose Versus High Dose.
Khater D; Al-Mulaabed S; Alomairi A; Elshinawy M; Soliman A; Elshinawy N; Wali Y; Al Yaarubi S
Hemoglobin; 2023 Nov; 47(4):157-162. PubMed ID: 37691435
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
15. Impact of hydroxyurea on clinical events in the BABY HUG trial.
Thornburg CD; Files BA; Luo Z; Miller ST; Kalpatthi R; Iyer R; Seaman P; Lebensburger J; Alvarez O; Thompson B; Ware RE; Wang WC;
Blood; 2012 Nov; 120(22):4304-10; quiz 4448. PubMed ID: 22915643
[TBL] [Abstract][Full Text] [Related]
16. Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.
Fung EB; Barden EM; Kawchak DA; Zemel BS; Ohene-Frempong K; Stallings VA
J Pediatr Hematol Oncol; 2001 Dec; 23(9):604-8. PubMed ID: 11902305
[TBL] [Abstract][Full Text] [Related]
17. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
18. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
[TBL] [Abstract][Full Text] [Related]
19. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
20. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
